AstraZeneca Receives EMA’s CHMP Positive Opinion Recommending Approval of Forxiga (dapagliflozin) for Symptomatic Chronic Heart Failure
Shots:
- The EMA’s CHMP positive opinion was based on the P-III (DELIVER) trial evaluating Forxiga vs PBO in 6263 patients with HF with LVEF ≥40% with/out T2D
- The results showed a 16.4% vs 19.5% reduction in the composite outcome of CV death or worsening of HF in patients with HFpEF & HFmrEF over a median follow-up of 2.3yrs. The treatment effect was consistent across the LVEF range without evidence of attenuation of effect by LVEF & the results were published in The NEJM
- In the pre-specified, patient-level, pooled analysis, Forxiga showed a 14% reduction in risk of CV death, death from any cause (10%) & total hHF (29%) over the median follow-up of 22mos. Forxiga was approved for HFrEF in 100+ countries globally incl. the US, the EU, China & Japan
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.